• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

    5/8/25 7:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email

    HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019.

    Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer, will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET).

    To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at [email protected].

    About Plus Therapeutics

    Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

    About CNSide Diagnostic, LLC

    CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide™, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide™ CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide™ in the U.S. in 2025.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "expect" "potential," "anticipating," "planning" and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

    These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company's future performance, including the next steps in developing the Company's product candidates; the Company's clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts.

    The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies; the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash; the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company's clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact



    CORE IR

    [email protected]



    Primary Logo

    Get the next $PSTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/17/24 7:00:04 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/16/24 7:00:03 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/13/24 6:04:12 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clowes Howard

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:10 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Hawkins Richard J

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Petersen Greg

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

      AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

      2/20/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

      Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

      6/7/24 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

      HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer, will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City,

      5/8/25 7:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

      HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the online availability of new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) in an abstract for both an oral presentation and a poster to be presented at the Nuclear Medicine and Neurooncology conference to be held May 9-10, 2025 in Vienna, Austria. The abstract, titled, "Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases," highlights additional data from the Company's completed Phase 1 ReSPECT-LM dose es

      4/15/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

      SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      6/5/24 7:26:01 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/13/23 3:25:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/11/22 7:53:23 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Financials

    Live finance-specific insights

    See more
    • Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece

      3/27/25 4:05:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, March 27, 2025 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/5r5hkcqqDial-in

      3/19/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) ca

      11/14/24 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

      D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

      3/17/25 7:41:57 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright initiated coverage on Plus Therapeutics

      HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

      2/11/21 7:44:56 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

      2/11/21 6:52:36 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    SEC Filings

    See more
    • PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      5/2/25 4:05:08 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PLUS THERAPEUTICS Inc.

      DEFA14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      5/1/25 10:06:06 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by PLUS THERAPEUTICS Inc.

      10-K/A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      4/30/25 4:05:14 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care